In the phase 3 ALTA-1L trial (NCT02737501) comparing brigatinib and crizotinib in patients with ALK TKI-naive NSCLC, the primary end point, assessed by blinded independent review committee (BIRC), was met at the first interim analysis [10]. This evidence concerns the gene ALK and non-small cell lung carcinoma.